{"id":"bivalirudin-clopidogrel-aspirin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Dyspnea"}]},"_chembl":{"chemblId":"CHEMBL5314348","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bivalirudin is a direct thrombin inhibitor that prevents the conversion of fibrinogen to fibrin and platelet activation. Clopidogrel is a P2Y12 receptor antagonist that blocks platelet aggregation, and aspirin irreversibly inhibits cyclooxygenase to prevent thromboxane A2 synthesis. Together, this triple anticoagulant/antiplatelet regimen provides potent antithrombotic effects used during acute coronary interventions.","oneSentence":"This combination inhibits blood clotting through three complementary pathways: bivalirudin directly blocks thrombin, while clopidogrel and aspirin inhibit platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:03.299Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome undergoing percutaneous coronary intervention"},{"name":"Prevention of thrombotic complications during coronary angioplasty"}]},"trialDetails":[{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT00669149","phase":"PHASE4","title":"Anticoagulant Treatments and Percutaneous Coronary Angioplasty","status":"TERMINATED","sponsor":"Centre Hospitalier de PAU","startDate":"2008-06","conditions":"Coronary Artery Disease","enrollment":99},{"nctId":"NCT02384070","phase":"NA","title":"Simplified Anti-Thrombotic Therapy for FFR","status":"COMPLETED","sponsor":"Odessa Heart Institute","startDate":"2009-01","conditions":"Coronary Artery Disease","enrollment":300},{"nctId":"NCT01642238","phase":"PHASE4","title":"Antithrombotic Effects of Ticagrelor Versus Clopidogrel","status":"COMPLETED","sponsor":"Juan J Badimon","startDate":"2012-07","conditions":"Acute Coronary Syndrome","enrollment":15},{"nctId":"NCT02268669","phase":"PHASE4","title":"Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI","status":"UNKNOWN","sponsor":"GRACIA Group","startDate":"2010-05","conditions":"Myocardial Infarction","enrollment":1444},{"nctId":"NCT00398463","phase":"PHASE4","title":"Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2006-05","conditions":"Angioplasty, Transluminal, Percutaneous Coronary","enrollment":263},{"nctId":"NCT01157455","phase":"PHASE4","title":"A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization","status":"UNKNOWN","sponsor":"CCRF Consulting Co., Ltd.","startDate":"2010-05","conditions":"Coronary Artery Diseases","enrollment":1900}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Angiox Plavix Kardégic"],"phase":"marketed","status":"active","brandName":"bivalirudin + clopidogrel + aspirin","genericName":"bivalirudin + clopidogrel + aspirin","companyName":"Centre Hospitalier de PAU","companyId":"centre-hospitalier-de-pau","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits blood clotting through three complementary pathways: bivalirudin directly blocks thrombin, while clopidogrel and aspirin inhibit platelet aggregation. Used for Acute coronary syndrome undergoing percutaneous coronary intervention, Prevention of thrombotic complications during coronary angioplasty.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}